Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dave who wrote (269)	4/22/2002 4:02:59 PM
From: Jim Oravetz	Read Replies (1) of 370

Vion Pharma Reports Patent Office Decision DOW JONES NEWSWIRES NEW HAVEN, Conn. -- Vion Pharmaceuticals Inc. (VION ) said the U.S. Patent and Trademark Office awarded priority of invention to BioChem Pharma Inc. with respect to a method for administering 3TC and to a method for administering BCH-189 to treat hepatitis B. In a press release Monday, Vion Pharmaceuticals said the patent isn't related to any of its three cancer compounds currently in clinical trials, which have been the company's primary focus. The Board of Patent and Interferences issued the decision after BioChem proved that all of its rights were transferred when it merged into a new company, Shire BioChem Inc. Vion's request for an interference declaration was granted in November 1999 in connection with a conflict between an application licensed to Vion and a patent assigned to BioChem Pharma. The Vion-licensed application is also involved in an interference with an application owned by GlaxoSmithKline PLC (GSK) involving patent rights to a method for administering BCH-189 or 3TC to treat hepatitis B. An interference is a legal proceeding that determines which party is entitled to a patent when two or more parties make similar filings. Shares of Vion closed Monday at $3.70, down 6 cents, or 1.6%, on Nasdaq SmallCap volume of 38,000 shares. Average daily volume is 62,223 shares. Company Web site: vionpharm.com Don't think this is the reason, but then maybe someone big (just look at the volume) thought that Vion would win on this issue and the stock would go up on the news. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next